Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 33Multiple Myeloma 23Leukemia, Myeloid, Acute 23Lymphoma 17Colorectal Neoplasms 16Breast Neoplasms 15Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Triple Negative Breast Neoplasms 10Prostatic Neoplasms 10Burkitt Lymphoma 10Sarcoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Ovarian Neoplasms 8Lymphoma, T-Cell 8Lymphoma, Large B-Cell, Diffuse 8Glioma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Neuroblastoma 6Melanoma 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × Biopsy × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡